SNYNF Quote, Financials, Valuation and Earnings

DBV Technologies SA has a net margin of 36.7% compared to Sanofi's net margin of --. Sanofi's return on equity of 12.45% beat DBV Technologies SA's return on equity of -280.59%.

Sanofi has a consensus price target of --, signalling upside risk potential of 30.87%. On the other hand DBV Technologies SA has an analysts' consensus of $20.57 which suggests that it could grow by 58.35%. Given that DBV Technologies SA has higher upside potential than Sanofi, analysts believe DBV Technologies SA is more attractive than Sanofi.

Sanofi has a beta of 0.224, which suggesting that the stock is 77.582% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -1.102, suggesting its less volatile than the S&P 500 by 210.179%.

Sanofi has a quarterly dividend of $4.35 per share corresponding to a yield of 4.44%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi pays 88.23% of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend. Sanofi's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi quarterly revenues are $12.2B, which are larger than DBV Technologies SA quarterly revenues of --. Sanofi's net income of $4.5B is higher than DBV Technologies SA's net income of -$33M. Notably, Sanofi's price-to-earnings ratio is 12.23x while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi is 2.82x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Innate Pharma SA has a net margin of 36.7% compared to Sanofi's net margin of --. Sanofi's return on equity of 12.45% beat Innate Pharma SA's return on equity of -72.79%.

Sanofi has a consensus price target of --, signalling upside risk potential of 30.87%. On the other hand Innate Pharma SA has an analysts' consensus of $5.15 which suggests that it could grow by 171.26%. Given that Innate Pharma SA has higher upside potential than Sanofi, analysts believe Innate Pharma SA is more attractive than Sanofi.

Sanofi has a beta of 0.224, which suggesting that the stock is 77.582% less volatile than S&P 500. In comparison Innate Pharma SA has a beta of -0.081, suggesting its less volatile than the S&P 500 by 108.148%.

Sanofi has a quarterly dividend of $4.35 per share corresponding to a yield of 4.44%. Innate Pharma SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi pays 88.23% of its earnings as a dividend. Innate Pharma SA pays out -- of its earnings as a dividend. Sanofi's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi quarterly revenues are $12.2B, which are larger than Innate Pharma SA quarterly revenues of --. Sanofi's net income of $4.5B is higher than Innate Pharma SA's net income of --. Notably, Sanofi's price-to-earnings ratio is 12.23x while Innate Pharma SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi is 2.82x versus 24.54x for Innate Pharma SA. Usually stocks with elevated PS ratios are considered overvalued.

Inventiva SA has a net margin of 36.7% compared to Sanofi's net margin of --. Sanofi's return on equity of 12.45% beat Inventiva SA's return on equity of --.

Sanofi has a consensus price target of --, signalling upside risk potential of 30.87%. On the other hand Inventiva SA has an analysts' consensus of $15.33 which suggests that it could grow by 270.37%. Given that Inventiva SA has higher upside potential than Sanofi, analysts believe Inventiva SA is more attractive than Sanofi.

Sanofi has a beta of 0.224, which suggesting that the stock is 77.582% less volatile than S&P 500. In comparison Inventiva SA has a beta of 0.746, suggesting its less volatile than the S&P 500 by 25.433%.

Sanofi has a quarterly dividend of $4.35 per share corresponding to a yield of 4.44%. Inventiva SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi pays 88.23% of its earnings as a dividend. Inventiva SA pays out -- of its earnings as a dividend. Sanofi's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi quarterly revenues are $12.2B, which are larger than Inventiva SA quarterly revenues of --. Sanofi's net income of $4.5B is higher than Inventiva SA's net income of --. Notably, Sanofi's price-to-earnings ratio is 12.23x while Inventiva SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi is 2.82x versus 24.10x for Inventiva SA. Usually stocks with elevated PS ratios are considered overvalued.